Norovirus Outbreak: A New Vaccine on the Horizon
As the norovirus continues to wreak havoc across the United States this winter, a potential game-changer is emerging. Moderna, a biotech company, is currently conducting a large phase three trial of a norovirus vaccine, with results expected as early as this year or 2026.
The Urgent Need for a Vaccine
Norovirus, a highly contagious and debilitating stomach bug, has been spreading rapidly this season. According to the Centers for Disease Control and Prevention (CDC), twice as many norovirus tests are coming back positive this January compared to the same time last year. The CDC also reports a 36% increase in norovirus outbreaks so far this season.
Moderna’s Vaccine Candidate
Moderna’s vaccine candidate targets the three most common genotypes of norovirus, which are responsible for the majority of infections. The vaccine works by introducing a harmless, non-infectious version of the virus to the immune system, allowing it to learn how to fight back against future infections. Although the vaccine doesn’t include the genotype responsible for this year’s outbreaks, the study aims to determine if it provides protection against other types of norovirus as well.
The Goal: Reducing Severity, Not Eliminating Infection
Moderna’s goal is not to completely prevent norovirus infections, but to reduce the severity of symptoms and prevent hospitalizations. The company believes that vaccinating seniors, who are particularly vulnerable to norovirus complications, could have a significant impact. Health-care workers, daycare workers, and people going on cruises are also potential target populations.
Commercial Viability and Future Possibilities
While investors are questioning the commercial viability of the vaccine, Moderna sees a significant opportunity in protecting vulnerable populations. If the vaccine proves effective, the company may also explore testing it in children, who are also susceptible to norovirus.
A Potential Breakthrough
As the norovirus outbreak continues to spread, Moderna’s vaccine candidate offers a glimmer of hope. With results expected soon, the medical community and investors alike are eagerly awaiting the outcome of this critical trial.
Leave a Reply